NewsBenzingaRevolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC Benzinga 2026.10.05 12:02 (GMT+0) Open on Benzinga Other news Stocks Supported by a Rebound in Chipmakers and AI-Infrastructure Companies Taiwan’s President Called on Micron and Workers to Negotiate Ahead of a Possible Strike. Here’s What to Know. 3 Token Unlocks to Watch in the Fourth Week of October 2026 Rocket Lab's Biggest Technological Advantage Is Fast Becoming Its Biggest Problem Why Is IREN Stock Surging Monday? Venture Global Stock Just Secured a Data Center Win. How to Play It Here.
Taiwan’s President Called on Micron and Workers to Negotiate Ahead of a Possible Strike. Here’s What to Know.
